FN1 EDB

CI-VAR-00000871Explore in graph →CIViC 3484

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Melanoma3
FN1 EDB	Daromun	Predictive	B	Supports Sensitivity Response	4	submitted	EID9624 In a clinical trial including 20 patients and 105 lesions, intralesional administration of L19IL2/L19TNF shows 30.5% CR, 17.1% PR, 25.7% SD, 5.7% PD and 21% non-CR. PMID 25971540 · Danielli et al., 2015 · Open in CIViC	civic
FN1 EDB	L19IL2	Predictive	B	Supports Sensitivity Response	4	submitted	EID9626 In a clinical study including 25 patients, patients treated with L19IL2 show 44.4% irCR, 9.5% irPR, 36.5% ires ans 9.5% irPD. PMID 24906352 · Weide et al., 2014 · Open in CIViC	civic
FN1 EDB	Dacarbazine + L19IL2Combination

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.